# **SPECIFICATION**

Electronic Version 1.2.8 Stylesheet Version 1.0

# SOY HYDROLYSATE BASED NUTRITIONAL FORMULATIONS

#### Background of the Invention

- [0001] The present invention relates generally to products for providing nutritional support. More specifically, the present invention relates to infant formulas and other specialized nutritional supplements.
- [0002] It is of course known to provide enteral nutrition to an individual. Such nutrition can be provided to either afford the complete nutrition requirements to the individual or as a supplement. In a similar vein, these products can either be directed to the population in general or individuals having special requirements. For example, due to disease states or other abnormalities, individuals may not be able to tolerate certain components that may be typical of most nutritional formulations.
- [0003] One type of enteral nutrition is infant formulas. Infant formulas are designed to provide nutritional support to pre-term, full-term, and post-term babies. Typically, infant formulas are directed to individuals under the age of 12 months. These formulas are either designed as a substitute for or a supplement to human breast milk. Such formulations can provide the total nutritional support for an infant or they can be used to supplement an infant's diet.
- [0004] Similar to the adult population, some infants are allergic to milk-based products. For example, a number of individuals have an intolerance to regular milk formulas. This is typically due to the proteins and/or lactose in the regular milk formulas. It is therefore known to provide infant formulas based on soy proteins; soy can be used as a substitute for milk.

[0005] Additionally, infants do not have fully developed digestive systems. Certain nutritional components, for example, protein, may be difficult for infants to digest during their early development.

### Summary of the Invention

- [0006] The present invention provides improved nutritional formulations. In a preferred embodiment, the present invention provides an infant formula that is preferably lactose free as well as is designed to be more easily digested by infants.
- [0007] To this end, in an embodiment, the present invention provides an infant formula that is lactose free comprising hydrolyzed soy protein isolate.
- [0008] In an embodiment, the soy hydrolysate isolate has a degree of hydrolysis of approximately 4 to about 10%.
- [0009] In an embodiment, a stabilizer system is provided based on rice starch.
- [0010] In an embodiment, a stabilizer system is provided based on corn starch.
- [0011] In an embodiment, the soy hydrolysate isolate comprises not less than 50% by weight of the protein of the formula.
- [0012] In an embodiment, based on a ready-to-use basis, the formula includes approximately 0.5 to about 5% by weight protein.
- [0013] In an embodiment based on a ready-to-use basis: the formula includes approximately 0.5% to about 5% by weight protein; approximately 1% to about 10% carbohydrate; and approximately 1% to about 10% fat.
- [0014] In another embodiment, the present invention provides an infant formula including: a protein source that provides approximately 0.5 to about 10% based on weight of the formula and includes soy hydrolysate isolate; a carbohydrate source; a fat source; a stabilizer system; and vitamins and minerals.
- [0015]

  Additionally, in an embodiment, the present invention provides a method of providing an infant formula that is lactose free and more easily digested by an

infant than at least some other lactose free infant formulas comprising the steps of using as a protein source soy hydrolysate.

- [0016] An advantage of the present invention is to provide an improved infant formula.
- [0017] Another advantage of the present invention is to provide an improved infant formula for infants that is easier to digest.
- [0018] Still further, an advantage of the present invention is to provide a lactose-free infant formula.
- [0019] Furthermore, an advantage of the present invention is to provide an infant formula that functions as a comfort product.
- [0020] Moreover, an advantage of the present invention is to provide an enteral formulation that is more easily digested.
- [0021] A further advantage of the present invention is to provide a method for providing nutrition to an individual having lactose intolerance.
- [0022] Additional features and advantages of the present invention will be described in and apparent from the detailed description of the invention.

## **Detailed Description of the Invention**

- [0023] As noted above, in the preferred embodiment set forth below, the present invention provides improved infant formulas and methods for providing nutrition to infants. However, it should be noted, the present invention can be used to construct other dietary supplements for providing enteral nutrition to other individuals requiring lactose free and protein rich supplements that are easy to digest, e.g., adults.
- Pursuant to an embodiment of the present invention an infant formula is provided that is lactose free. Thus, the formula can be provided to infants having an intolerance to regular milk formulas. In addition, the formula is designed to provide more easily digestible proteins. Thus, the formula can be used with

infants, or other individuals that may have difficulties digesting proteins. For example, the formula can be used with infants that may be fussy due to an intolerance to regular soy protein formulas.

- [0025] The present invention provides a soy hydrolysate based infant formula. It has been discovered that by providing hydrolyzed soy that a soy-based formula can be provided that is more easily digested and better tolerated and may have at least reduced allergenicity potential.
- [0026] If desired, soy can comprise all of the protein source of the product. In an embodiment, soy comprises approximately 25% to about 75% by weight of the protein source of the product. In an embodiment, soy comprises up to approximately 50% by weight of the protein component of the formula. In an embodiment, the soy comprises 30% by weight of the total protein of the formula.
- [0027] A number of soy hydrolysates can be utilized. Preferably, the soy is hydrolyzed to a moderate degree. For example, the hydrolysis, as measured by degree of hydrolysis, is preferably in the range of approximately 4 to about 10% and most preferably approximately 5 to about 8%. With a hydrolysis of, for example, 4 to 7%, it has been found that the cleaving of the soy proteins is sufficient to reduce the majority of whole soy proteins to peptides as determined by gel electrophoresis and peptide profile. Hydrolyzed soy isolate is available from Protein Technologies International (St. Louis, Missouri).
- [0028] By way of example, and not limitation, embodiments of soy protein hydrolysate profiles are set forth below. Table 1 sets forth the soy protein hydrolysate specifications for an embodiment of the product.

  [t1]

Table 1. Soy Protein Hydrolysate Specifications

Per 100 grams		
65-90		
0.5-20		

Moisture	8 maximum
Calcium	0.5-3.0
Phosphorus	0.5-3.0
Sodium	2 maximum
Potassium	0.5-3.0

[0029] Table 2 sets forth an embodiment of the amino acid profile of a preferred soy protein hydrolysate.

[t2]

Table 2. Amino Acid Profile of Soy Protein Hydrolysate

	g/100 g
Alanine	4.20
Arginine	7.70
Aspartic Acid	11.30
Cysteine	1.20
Glutamic Acid	19.00
Glycine	4.00
Histidine	2.60
Isoleucine	4.80
Leucine	8.00
Lysine	6.10
Methionine	1.20
Phenylalanine	5.30
Proline	5.70
Serine	5.20
Threonine	3.70
Tryptophan	1.40
Tyrosine	3.70

[0030] Table 3 sets forth the molecular weight distribution of a soy hydrolysate that has been found to function satisfactorily.

[t3]

Table 3. Molecular Weight Distribution

Molecular Weight Distribution	% Peptides	
Mol. Wt. In Daltons	Average	Range
>50000	5	4-7
5000-50000	48	44-51
1500-5000	25	23-27
<500	22	19-25
Degree of Hydrolysis	5.5	4.0-7.0

[0031] As noted, the above soy hydrolysate can be either the entire protein source or a protein thereof. The protein source can comprise, in an embodiment, approximately 0.5% to about 5% by weight of a ready-to-use formula of the present invention. For a concentrate, this level, in an embodiment of the present invention, would be approximately 1.0 to about 10% by weight of the product.

[0032] In view of the soy hydrolysate, one of the issues with respect to the product is providing a stabilizer system. Pursuant to an embodiment of the present invention, neutral rice starch is utilized to stabilize the formula emulsion. Neutral rice starch provides stability as well as better hydration conditions and allows the product to be heat sterilized without degradation. In an embodiment, the stabilizer system is high amylose corn starch, kappa, or iota carragenan. However, it should be noted that a variety of stabilizer systems can be used. Such systems ideally should allow the product to be both aseptic and retort processable.

[0033]
A number of stabilizer systems have been explored. By way of example, and not limitation, the physical stability of aseptic and retort processed soy hydrolysis-


based infant formulas, based on the above soy hydrolysates, at the end of one month are set forth below in Table 4.

[0034] Table 4. Physical Stability of Aseptic and Retort Processed Soy Hydrolysate Based Infant Formula at the End of One Month

	Aseptic Product (Concentrate)			Retorted Product (RTF)		
			Phase Separation			
	Serum	Cream	Remarks	Top	Bottom	Remarks
System	(score l (	best) - 5)		%, phase		
250 PPM kappa-carrageenan	3	3		64	36	
250 PPM kappa-carrageenan (higher	3	3		64	36	1
pre-process temp & time)						
200 PPM kappa-carrageenan and 100	3	2.5		41	59	
PPM iota-carrageenan		[			ĺ	
2% Modified Starch	3	3		27	73	
2% Modified Starch + 200 PPM iota-	2.5	2		18	72	
carrageenan					[	
2% Rice Starch + 200 PPM iota-	3	3.5		23	77	
carrageenan						{
2% Corn Starch (high amylose) + 200	1.75	1	Good	41	59	
PPM iota-carrageenan						
2% Corn Starch (high amylose) + 250	1.25	1.5	Good	41	59	
PPM iota-carrageenan		]				
1.2% Com Starch (high amylose) +	1.25	1.5	Good	Homo	geneous	Good
100 PPM iota-carrageenan + 150 PPM						
kappa-carrageenan						}
1.2% Corn Starch (high amylose), 250	1.25	1	Good	20	80	Good
PPM iota-carrageenan					ļ	
2% Corn Starch (high amylose), 250	1.25	1	Good	41	59	
PPM iota-carrageenan						
1.2% Corn Starch (high amylose), 250	1.25	1.5	Good	45	55	
PPM iota-carrageenan	V					}
1.2% Corn Starch (high amylose), 100	1.25	1.5	Good	27	73	Good
PPM iota-carrageenan, 150 PPM					}	
kappa-carrageenan		)			ļ	
1.2% Corn Starch (high amylose), 250	1.25	1.5	Good	15	85	Good
PPM kappa-carrageenan		)				)

[0035] In addition to the protein source and stabilizer, the product will also include necessary macro and micronutrients to provide a complete nutritional product. In an embodiment of the present invention, a ready-to-use product will include approximately 1% to about 15% by weight carbohydrates. As a concentrate, in an embodiment of the present invention, the carbohydrates will comprise approximately 5% to about 20% by weight of the product.

[0036] In an embodiment of the present invention, the ready-to-use product will comprise approximately 1% to about 10% by weight fat. In an embodiment of the present invention as a concentrate, the product will comprise approximately 4 to about 20% by weight of fat.



[0038] Set forth below are tables illustrating ready-to-feed formulas, concentrated infant formulas, and powdered infant formulas. Each of the tables sets forth embodiments of the formulations. In this regard, each of the tables sets forth, embodiments of possible ranges of each of the components.

[0039] Table 5. Ready-to-Feed Formula

	Dry matter basis % by weight					
RAW MATERIALS	Preferable Ranges Preferred Ranges					
	Upper	Lower	Upper	Lower		
PO				***************************************		
RO water Maltrin M-180	7.604	1.901	6.178	3.327		
	4.436	0.887	2.883	1.553		
Soy hydrolysate isolate	Up to 50% of		2.003 Up to 30% of			
Intact Soy Isolate	2.327	0.582	1.890	1.018		
Sucrose	2.327	0.557	1.809	0.974		
Palm Olein oil		1	1.013	0.545		
Soybean oil	1.247	0.312	0.796	0.343		
Coconut oil	0.980	0.245				
Corn Starch (High amylose)	0.885	0.221	0.719	0.387		
H.O. Safflower Oil	0.276	0.069	0.225	0.121		
Soy Lecithin, 3 FUB	0.262	0.066	0.213	0.115		
Dimodan BPT/K	0.218	0.054	0.177	0.095		
Potassium Chloride	0.123	0.031	0.100	0.054		
Sodium Citrate	0.111	0.028	0.091	0.049		
Calcium Citrate, 4H2O	0.081	0.020	0.065	0.035		
Sodium ascorbate	0.057	0.014	0.046	0.025		
L-Methionine	0.039	0.010	0.031	0.017		
Choline Bitartrate	0.028	0.007	0.023	0.012		
Inositol	0.023	0.006	0.019	0.010		
Magnesium Chloride 6H2O	0.018	0.004	0.014	0.008		
Potassium Citrate	0.0155	0.0039	0.0126	0.0068		
Kappa-Carrageenan	0.0203	0.0027	0.0088	0.0047		
Tauring	0.0105	0.0026	0.0085	0.0046		
Alpha tocopherol acetate	0.0101	0.0025	0.0082	0.0044		
Iota-Carrageenan	0.0135	0.0018	0.0059	0.0032		
Ferrous sulfate	0.0057	0.0014	0.0047	0.0025		
Magnesium Oxide	0.0051	0.0013	0.0041	0.0022		
L-Carnitine	0.0033	0.0008	0.0027	0.0015		
Zinc sulfate	0.0025	0.0006	0.0021	0.0011		
Niacinamide	0.0025	0.0006	0.0020	0.0011		
Vitamin A acetate	0.0018	0.0005	0.0015	0.0008		
Vitamin K1	0.001548	0.000387	0.001258	0.000677		
Beta carotene	0.001371	0.000343	0.001114	0.000600		
Vit. D3	0.000912	0.000228	0.000741	0.000399		
Pantothenic acid	0.000912	0.000220	0.000686	0.000369		
Potassium iodide	0.000283	0.000071	0.000230	0.000124		
Copper sulfate	0.000243	0.000071	0.000198	0.000124		
Riboflavin	0.000176	0.000044	0.000133	0.000107		
Thiamine hydrochloride	0.000176	0.000034	0.000143	0.000059		
	0.000133	0.000034	0.000110	0.000054		
Pyridoxine hydrochloride		0.000031	0.000100	0.000034		
Cobalamin	0.000061	0.000013		0.000027		
Folic Acid	0.000035	A	0.000029			
Biotin	0.000013	0.000003	0.000011	0.000006		
Sodium selenate	0.000006	0.000001	0.000005	0.000002		

[0040] Table 6. Concentrate Infant Formula

	Dry matter basis % by weight					
RAW MATERIALS	Preferre	ble Ranges	Prefere	ed Ranges		
	Upper	Lower	Upper	Lower		
RO water						
Maltrin M-180	14.860	3.715	12073	6.301		
Soy hydrolysate isolate	6.931	1.733	5.632	3.032		
Intact Soy Isolate	Up to 50% or		Un to 30% of	total protein		
Sucrose	4.544	1.136	3.692	1.988		
Palm Olein oil	4.348	1.087	3.533	1.902		
Soybean oil	2.435	0.609	1 978	1.065		
Coconut oil	1.913	0.478	1.554	0.837		
Com Starch (High amylose)	1.728	0.432	1.404	0.756		
H.O. Safflower Oil	0.540	0.135	0.439	0.236		
Sov Lecithin, 3 FUB	0.512	0.128	0.416	0.224		
Dimodan BPT/K	0.426	0.106	0.346	0.186		
Potassium Chloride	0.240	0.060	0.195	0.105		
Sodium Citrate	0.218	0.054	0.177	0.095		
Calcium Citrate, 4H2O	0.157	0.039	0.128	0.069		
Sodium ascorbate	0.111	0.028	0.090	0.049		
L-Methionine	0.075	0.019	0.061	0.033		
Choline Bitartrate	0.054	0.014	0.044	0.024		
Inositol	0.045	0.011	0.037	0.020		
Magnesium Chloride 6H2O	0.034	0.009	0.028	0.015		
Potassium Citrate	0.0302	0.0076	0.0246	0.0132		
Kappa-Canageenan	0.0396	0.0053	0.0172	0.0092		
Taurine	0.0204	0.0051	0.0166	0.0089		
Alpha tocopherol acetate	0.0197	0.0049	0.0160	0.0086		
Iota-Carrageenan	0.0264	0.0035	0.0114	0.0062		
Ferrous sulfate	0.0112	0.0028	0.0091	0.0049		
Magnesium Oxide	0.0099	0.0025	0.0080	0.0043		
L-Carntine	0.0065	0.0016	0.0053	0.0028		
Zinc sulfate	0.0050	0.0012	0.0040	0.0022		
Niacinamide	0.0049	0.0012	0.0040	0.0022		
Vitamin A acetate	0.0035	0.0009	0.0029	0.0015		
Vitamin Kl	0.003024	0.000756	0.002457	0.00132		
Beta carotene	0.002678	0.000670	0.002176	0.001172		
Vit. D3	0.001782	0.000446	0.001448	0.000780		
Pantothenic acid	0.001648	0.000412	0.001339	0.000721		
Potassium iodide	0.000553	0.000138	0.000449	0.000242		
Copper sulfate	0.000475	0.000119	0.000386	0.000208		
Riboflavin	0.000343	0.000086	0.000279	0.000150		
Thiamine hydrochloride	0.000264	0.000066	0.000214	0.00011		
Pyridoxine hydrochloride	0.000240	0.000060	0.000195	0.00010		
Cobalamin	0.000119	0.000030	0.000097	0.000052		
Folic Acid	0.000069	0.000017	0.0000056	0.000030		
Biotin	0.000026	0.000006	0.000021	0.000011		
Sodium selenate	0.000011	0.000003	0.000009	0.000003		

[0041]

Table 7. Powder Infant Formula

	Dry matter basis % by weight					
RAW MATERIALS	Prefera	ble Range	Preferred Range			
	Upper	Lower	Upper	Lower		
Maltrin M-180	66.188	16.547	53.778	28.957		
Soy hydrolysate isolate	27.267	6.817	22.154	11.929		
Intact Soy Isolate	Up to 50 % o	f total protein	Up to 30 % of	total protein		
Sucrose	17.994	4.499	14.620	7.872		
Pelm Olein oil	17.978	4.495	14.607	7.866		
Sovbean oil	10.068	2.517	8.180	4.405		
Coconut oil	7.910	1.978	6.427	3.461		
H.O. Safflower Oil	2.232	0.558	1.813	0.976		
Soy Lecithin, 3 FUB	2.028	0.507	1.647	0.887		
Dimodan BPT/K	0.000	0.000	0.000	0.000		
Potassium Chloride	0.950	0.238	0.772	0.416		
Sodium Citrate	0.862	0.215	0.700	0.377		
Calcium Citrate, 4H2O	0.626	0.157	0.509	0.274		
Sodium ascorbate	0.440	0.110	0.358	0.193		
L-Methionine	0.298	0.074	0.242	0.130		
Choline Bitartrate	0.215	0.054	0.175	0.094		
Inositol	0.180	0.045	0.146	0.079		
Magnesium Chloride 6H2O	0.137	0.034	0.111	0.060		
Potassium Citrate	0.1197	0.0299	0.0972	0.0524		
Taurine	0.0808	0.0202	0.0657	0.0354		
Alpha tocopherol acetate	0.0780	0.0195	0.0634	0.0341		
Ferrous sulfate	0.0444	0.0111	0.0361	0.0194		
Magnesium Oxide	0.0392	0.0098	0.0318	0.0171		
L-Carnitine	0.0257	0.0064	0.0208	0.0112		
Zinc sulfate	0.0197	0.0049	0.0160	0.0086		
Niacinamide	0.0195	0.0049	0.0158	0.0085		
Vitamin A acetate	0.0140	0.0035	0.0114	0.0061		
Vitamin K1	0.011975	0.002994	0.009730	0.005239		
Beta carotene	0.010606	0.002652	0.008618	0.004640		
Vit. D3	0.007057	0.001764	0.005734	0.003087		
Pantothenic acid	0.006526	0.001632	0.005303	0.002855		
Potassium iodide	0.002190	0.000547	0.001779	0.000958		
Copper sulfate	0.001883	0.000471	0.001530	0.000824		
Riboflavin	0.001360	0.000340	0.001105	0.000595		
Thiamine hydrochloride	0.001044	0.000261	0.000848	0.000457		
Pyridoxine hydrochloride	0.000949	0.000237	0.000771	0.000415		
Cobalamin	0.000470	0.000118	0.000382	0.000206		
Folic acid	0.000274	0.000068	0.000222	0.000120		
Biotin	0.000103	0.000026	0.000083	0.000045		
Sodium se lenate	0.000043	0.000011	0.000035	0.000019		

[0042] The present invention provides improved infant formulas. These infant formulas can be utilized either as a supplement to or complete nutrition for the infant. Additionally, as illustrated above, the infant formulas can be provided as a ready-to-use product, a concentrate, or a powder that needs to be reconstituted. The formulas are designed to provide comfort to an infant. As used herein, a comfort formula is one that is more easily digestible for an infant or other individual. Due to the use of hydrolyzed soy, these formulas are easier for infants to digest.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be

covered by the appended claims.